TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

Health

Cosmetics

Clinical Trials

Retail

Galderma

More Like This

Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines

ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)

IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position

Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe

Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence

AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio

Copyrights - Sylvain Granjon

Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event

Galderma Reports Record Net Sales of Over 3 B USD for the First Nine Months of 2023 With Strong Growth Momentum Across All Product Categories